12th Annual Guidelines for Disseminating Off-Label Information
October 5-6, 2010
Alexandria, VA
Program Highlights
- Learn about liability under RICO -- Understand the recent verdict against Pfizer related to off-label promotion of Neurontin
- Understand how efforts arising under HEAT at DOJ, HHS, OIG and FDA impact criminal investigations and civil False Claims Act cases
- Assess the high-risk areas for off-label requests and strengthen the role of the MSL in the exchange of scientific information
- Link Rx and ICD-9 data with longitudinal data to identify off-label prescribing patterns
- Identify trends in allegations, fines and penalties and newly required compliance obligations
- Hear directly from the Chief Compliance Officer at InterMune on the settlement with the DOJ and how they are operating under a CIA with the OIG
- Participate in a panel discussion that brings together all key stakeholders in an off-label case and plays out a hypothetical scenario
